img

Global Poliomyelitis Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Poliomyelitis Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Polio vaccines are vaccines used to prevent poliomyelitis. There are two typesone that uses inactivated poliovirus and is given by injection, and one that uses weakened poliovirus and is given by mouth.
The World Health Organization recommends all children be fully vaccinated against polio. The two vaccines have eliminated polio from most of the world, and reduced the number of cases reported each year from an estimated 350,000 in 1988 to 37 in 2016.
The global Poliomyelitis Vaccine market size was US$ 709.8 million in 2024 and is forecast to a readjusted size of US$ 835.1 million by 2034 with a CAGR of 2.3% during the forecast period 2024-2034.
Sanofi, GSK and Serum Institute are the top 3 players of Polio Vaccine with about 91% market shares.
In terms of sales (consumption) side, this report focuses on the sales of Poliomyelitis Vaccine by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Poliomyelitis Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Poliomyelitis Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


GSK
Sanofi-Pasteur
Merck
Crucell
China National Biotech Group
Eli Lilly
By Type
Poliomyelitis Vaccine Ⅰ
Poliomyelitis Vaccine Ⅱ
Poliomyelitis Vaccine Ⅲ
Oral Poliomyelitis Vaccine
By Application
VAPP
VDPV
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Poliomyelitis Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Poliomyelitis Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Poliomyelitis Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Poliomyelitis Vaccine Definition
1.2 Market by Type
1.2.1 Global Poliomyelitis Vaccine Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Poliomyelitis Vaccine Ⅰ
1.2.3 Poliomyelitis Vaccine Ⅱ
1.2.4 Poliomyelitis Vaccine Ⅲ
1.2.5 Oral Poliomyelitis Vaccine
1.3 Market Segment by Application
1.3.1 Global Poliomyelitis Vaccine Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 VAPP
1.3.3 VDPV
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Poliomyelitis Vaccine Sales
2.1 Global Poliomyelitis Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Poliomyelitis Vaccine Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Poliomyelitis Vaccine Revenue by Region
2.3.1 Global Poliomyelitis Vaccine Revenue by Region (2018-2023)
2.3.2 Global Poliomyelitis Vaccine Revenue by Region (2024-2034)
2.4 Global Poliomyelitis Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Poliomyelitis Vaccine Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Poliomyelitis Vaccine Sales Quantity by Region
2.6.1 Global Poliomyelitis Vaccine Sales Quantity by Region (2018-2023)
2.6.2 Global Poliomyelitis Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Poliomyelitis Vaccine Sales Quantity by Manufacturers
3.1.1 Global Poliomyelitis Vaccine Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Poliomyelitis Vaccine Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Poliomyelitis Vaccine Sales in 2024
3.2 Global Poliomyelitis Vaccine Revenue by Manufacturers
3.2.1 Global Poliomyelitis Vaccine Revenue by Manufacturers (2018-2023)
3.2.2 Global Poliomyelitis Vaccine Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Poliomyelitis Vaccine Revenue in 2024
3.3 Global Poliomyelitis Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Poliomyelitis Vaccine, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Poliomyelitis Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Poliomyelitis Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Poliomyelitis Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Poliomyelitis Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Poliomyelitis Vaccine Sales Quantity by Type
4.1.1 Global Poliomyelitis Vaccine Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Poliomyelitis Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Poliomyelitis Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Poliomyelitis Vaccine Revenue by Type
4.2.1 Global Poliomyelitis Vaccine Historical Revenue by Type (2018-2023)
4.2.2 Global Poliomyelitis Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Poliomyelitis Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Poliomyelitis Vaccine Price by Type
4.3.1 Global Poliomyelitis Vaccine Price by Type (2018-2023)
4.3.2 Global Poliomyelitis Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Poliomyelitis Vaccine Sales Quantity by Application
5.1.1 Global Poliomyelitis Vaccine Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Poliomyelitis Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Poliomyelitis Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Poliomyelitis Vaccine Revenue by Application
5.2.1 Global Poliomyelitis Vaccine Historical Revenue by Application (2018-2023)
5.2.2 Global Poliomyelitis Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Poliomyelitis Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Poliomyelitis Vaccine Price by Application
5.3.1 Global Poliomyelitis Vaccine Price by Application (2018-2023)
5.3.2 Global Poliomyelitis Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Poliomyelitis Vaccine Sales by Company
6.1.1 North America Poliomyelitis Vaccine Revenue by Company (2018-2023)
6.1.2 North America Poliomyelitis Vaccine Sales Quantity by Company (2018-2023)
6.2 North America Poliomyelitis Vaccine Market Size by Type
6.2.1 North America Poliomyelitis Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Poliomyelitis Vaccine Revenue by Type (2018-2034)
6.3 North America Poliomyelitis Vaccine Market Size by Application
6.3.1 North America Poliomyelitis Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Poliomyelitis Vaccine Revenue by Application (2018-2034)
6.4 North America Poliomyelitis Vaccine Market Size by Country
6.4.1 North America Poliomyelitis Vaccine Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Poliomyelitis Vaccine Revenue by Country (2018-2034)
6.4.3 North America Poliomyelitis Vaccine Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Poliomyelitis Vaccine Sales by Company
7.1.1 Europe Poliomyelitis Vaccine Sales Quantity by Company (2018-2023)
7.1.2 Europe Poliomyelitis Vaccine Revenue by Company (2018-2023)
7.2 Europe Poliomyelitis Vaccine Market Size by Type
7.2.1 Europe Poliomyelitis Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Poliomyelitis Vaccine Revenue by Type (2018-2034)
7.3 Europe Poliomyelitis Vaccine Market Size by Application
7.3.1 Europe Poliomyelitis Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Poliomyelitis Vaccine Revenue by Application (2018-2034)
7.4 Europe Poliomyelitis Vaccine Market Size by Country
7.4.1 Europe Poliomyelitis Vaccine Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Poliomyelitis Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Poliomyelitis Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Poliomyelitis Vaccine Sales by Company
8.1.1 China Poliomyelitis Vaccine Sales Quantity by Company (2018-2023)
8.1.2 China Poliomyelitis Vaccine Revenue by Company (2018-2023)
8.2 China Poliomyelitis Vaccine Market Size by Type
8.2.1 China Poliomyelitis Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Poliomyelitis Vaccine Revenue by Type (2018-2034)
8.3 China Poliomyelitis Vaccine Market Size by Application
8.3.1 China Poliomyelitis Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Poliomyelitis Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Poliomyelitis Vaccine Sales by Company
9.1.1 APAC Poliomyelitis Vaccine Sales Quantity by Company (2018-2023)
9.1.2 APAC Poliomyelitis Vaccine Revenue by Company (2018-2023)
9.2 APAC Poliomyelitis Vaccine Market Size by Type
9.2.1 APAC Poliomyelitis Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Poliomyelitis Vaccine Revenue by Type (2018-2034)
9.3 APAC Poliomyelitis Vaccine Market Size by Application
9.3.1 APAC Poliomyelitis Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Poliomyelitis Vaccine Revenue by Application (2018-2034)
9.4 APAC Poliomyelitis Vaccine Market Size by Region
9.4.1 APAC Poliomyelitis Vaccine Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Poliomyelitis Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Poliomyelitis Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Poliomyelitis Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Poliomyelitis Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Poliomyelitis Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Poliomyelitis Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 GSK
11.1.1 GSK Company Information
11.1.2 GSK Overview
11.1.3 GSK Poliomyelitis Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 GSK Poliomyelitis Vaccine Products and Services
11.1.5 GSK Poliomyelitis Vaccine SWOT Analysis
11.1.6 GSK Recent Developments
11.2 Sanofi-Pasteur
11.2.1 Sanofi-Pasteur Company Information
11.2.2 Sanofi-Pasteur Overview
11.2.3 Sanofi-Pasteur Poliomyelitis Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Sanofi-Pasteur Poliomyelitis Vaccine Products and Services
11.2.5 Sanofi-Pasteur Poliomyelitis Vaccine SWOT Analysis
11.2.6 Sanofi-Pasteur Recent Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck Overview
11.3.3 Merck Poliomyelitis Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Merck Poliomyelitis Vaccine Products and Services
11.3.5 Merck Poliomyelitis Vaccine SWOT Analysis
11.3.6 Merck Recent Developments
11.4 Crucell
11.4.1 Crucell Company Information
11.4.2 Crucell Overview
11.4.3 Crucell Poliomyelitis Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Crucell Poliomyelitis Vaccine Products and Services
11.4.5 Crucell Poliomyelitis Vaccine SWOT Analysis
11.4.6 Crucell Recent Developments
11.5 China National Biotech Group
11.5.1 China National Biotech Group Company Information
11.5.2 China National Biotech Group Overview
11.5.3 China National Biotech Group Poliomyelitis Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 China National Biotech Group Poliomyelitis Vaccine Products and Services
11.5.5 China National Biotech Group Poliomyelitis Vaccine SWOT Analysis
11.5.6 China National Biotech Group Recent Developments
11.6 Eli Lilly
11.6.1 Eli Lilly Company Information
11.6.2 Eli Lilly Overview
11.6.3 Eli Lilly Poliomyelitis Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Eli Lilly Poliomyelitis Vaccine Products and Services
11.6.5 Eli Lilly Poliomyelitis Vaccine SWOT Analysis
11.6.6 Eli Lilly Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Poliomyelitis Vaccine Value Chain Analysis
12.2 Poliomyelitis Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Poliomyelitis Vaccine Production Mode & Process
12.4 Poliomyelitis Vaccine Sales and Marketing
12.4.1 Poliomyelitis Vaccine Sales Channels
12.4.2 Poliomyelitis Vaccine Distributors
12.5 Poliomyelitis Vaccine Customers
13 Market Dynamics
13.1 Poliomyelitis Vaccine Industry Trends
13.2 Poliomyelitis Vaccine Market Drivers
13.3 Poliomyelitis Vaccine Market Challenges
13.4 Poliomyelitis Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Poliomyelitis Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Poliomyelitis Vaccine Ⅰ
Table 3. Major Manufacturers of Poliomyelitis Vaccine Ⅱ
Table 4. Major Manufacturers of Poliomyelitis Vaccine Ⅲ
Table 5. Major Manufacturers of Oral Poliomyelitis Vaccine
Table 6. Global Poliomyelitis Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Poliomyelitis Vaccine Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Poliomyelitis Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 9. Global Poliomyelitis Vaccine Revenue Market Share by Region (2018-2023)
Table 10. Global Poliomyelitis Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Poliomyelitis Vaccine Revenue Market Share by Region (2024-2034)
Table 12. Global Poliomyelitis Vaccine Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 13. Global Poliomyelitis Vaccine Sales by Region (2018-2023) & (K Units)
Table 14. Global Poliomyelitis Vaccine Sales Market Share by Region (2018-2023)
Table 15. Global Poliomyelitis Vaccine Sales by Region (2024-2034) & (K Units)
Table 16. Global Poliomyelitis Vaccine Sales Market Share by Region (2024-2034)
Table 17. Global Poliomyelitis Vaccine Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 18. Global Poliomyelitis Vaccine Sales Quantity Share by Manufacturers (2018-2023)
Table 19. Global Poliomyelitis Vaccine Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 20. Global Poliomyelitis Vaccine Revenue Share by Manufacturers (2018-2023)
Table 21. Global Poliomyelitis Vaccine Price by Manufacturers 2018-2023 (USD/Unit)
Table 22. Global Key Players of Poliomyelitis Vaccine, Industry Ranking, 2021 VS 2024
Table 23. Global Poliomyelitis Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Poliomyelitis Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Poliomyelitis Vaccine as of 2024)
Table 25. Global Key Manufacturers of Poliomyelitis Vaccine, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Poliomyelitis Vaccine, Product Offered and Application
Table 27. Global Key Manufacturers of Poliomyelitis Vaccine, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Poliomyelitis Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 30. Global Poliomyelitis Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 31. Global Poliomyelitis Vaccine Sales Quantity Share by Type (2018-2023)
Table 32. Global Poliomyelitis Vaccine Sales Quantity Share by Type (2024-2034)
Table 33. Global Poliomyelitis Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 34. Global Poliomyelitis Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Poliomyelitis Vaccine Revenue Share by Type (2018-2023)
Table 36. Global Poliomyelitis Vaccine Revenue Share by Type (2024-2034)
Table 37. Poliomyelitis Vaccine Price by Type (2018-2023) & (USD/Unit)
Table 38. Global Poliomyelitis Vaccine Price Forecast by Type (2024-2034) & (USD/Unit)
Table 39. Global Poliomyelitis Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 40. Global Poliomyelitis Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 41. Global Poliomyelitis Vaccine Sales Quantity Share by Application (2018-2023)
Table 42. Global Poliomyelitis Vaccine Sales Quantity Share by Application (2024-2034)
Table 43. Global Poliomyelitis Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 44. Global Poliomyelitis Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Poliomyelitis Vaccine Revenue Share by Application (2018-2023)
Table 46. Global Poliomyelitis Vaccine Revenue Share by Application (2024-2034)
Table 47. Poliomyelitis Vaccine Price by Application (2018-2023) & (USD/Unit)
Table 48. Global Poliomyelitis Vaccine Price Forecast by Application (2024-2034) & (USD/Unit)
Table 49. North America Poliomyelitis Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 50. North America Poliomyelitis Vaccine Sales Quantity by Company (2018-2023) & (K Units)
Table 51. North America Poliomyelitis Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 52. North America Poliomyelitis Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 53. North America Poliomyelitis Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 54. North America Poliomyelitis Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Poliomyelitis Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 56. North America Poliomyelitis Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 57. North America Poliomyelitis Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 58. North America Poliomyelitis Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Poliomyelitis Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 60. North America Poliomyelitis Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 61. North America Poliomyelitis Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Poliomyelitis Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 63. North America Poliomyelitis Vaccine Sales Quantity by Country (2024-2034) & (K Units)
Table 64. Europe Poliomyelitis Vaccine Sales Quantity by Company (2018-2023) & (K Units)
Table 65. Europe Poliomyelitis Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 66. Europe Poliomyelitis Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 67. Europe Poliomyelitis Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 68. Europe Poliomyelitis Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 69. Europe Poliomyelitis Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Poliomyelitis Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 71. Europe Poliomyelitis Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 72. Europe Poliomyelitis Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 73. Europe Poliomyelitis Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Poliomyelitis Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 75. Europe Poliomyelitis Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 76. Europe Poliomyelitis Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Poliomyelitis Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 78. Europe Poliomyelitis Vaccine Sales Quantity by Country (2024-2034) & (K Units)
Table 79. China Poliomyelitis Vaccine Sales Quantity by Company (2018-2023) & (K Units)
Table 80. China Poliomyelitis Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 81. China Poliomyelitis Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 82. China Poliomyelitis Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 83. China Poliomyelitis Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 84. China Poliomyelitis Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Poliomyelitis Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 86. China Poliomyelitis Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 87. China Poliomyelitis Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 88. China Poliomyelitis Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Poliomyelitis Vaccine Sales Quantity by Company (2018-2023) & (K Units)
Table 90. APAC Poliomyelitis Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 91. APAC Poliomyelitis Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 92. APAC Poliomyelitis Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 93. APAC Poliomyelitis Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 94. APAC Poliomyelitis Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Poliomyelitis Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 96. APAC Poliomyelitis Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 97. APAC Poliomyelitis Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 98. APAC Poliomyelitis Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Poliomyelitis Vaccine Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 100. APAC Poliomyelitis Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 101. APAC Poliomyelitis Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Poliomyelitis Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 103. APAC Poliomyelitis Vaccine Sales Quantity by Region (2024-2034) & (K Units)
Table 104. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Company (2018-2023) & (K Units)
Table 105. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 106. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Type (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 109. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Application (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 113. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 116. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity by Country (2024-2034) & (K Units)
Table 119. GSK Company Information
Table 120. GSK Description and Overview
Table 121. GSK Poliomyelitis Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 122. GSK Poliomyelitis Vaccine Product and Services
Table 123. GSK Poliomyelitis Vaccine SWOT Analysis
Table 124. GSK Recent Developments
Table 125. Sanofi-Pasteur Company Information
Table 126. Sanofi-Pasteur Description and Overview
Table 127. Sanofi-Pasteur Poliomyelitis Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 128. Sanofi-Pasteur Poliomyelitis Vaccine Product and Services
Table 129. Sanofi-Pasteur Poliomyelitis Vaccine SWOT Analysis
Table 130. Sanofi-Pasteur Recent Developments
Table 131. Merck Company Information
Table 132. Merck Description and Overview
Table 133. Merck Poliomyelitis Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 134. Merck Poliomyelitis Vaccine Product and Services
Table 135. Merck Poliomyelitis Vaccine SWOT Analysis
Table 136. Merck Recent Developments
Table 137. Crucell Company Information
Table 138. Crucell Description and Overview
Table 139. Crucell Poliomyelitis Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 140. Crucell Poliomyelitis Vaccine Product and Services
Table 141. Crucell Poliomyelitis Vaccine SWOT Analysis
Table 142. Crucell Recent Developments
Table 143. China National Biotech Group Company Information
Table 144. China National Biotech Group Description and Overview
Table 145. China National Biotech Group Poliomyelitis Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 146. China National Biotech Group Poliomyelitis Vaccine Product and Services
Table 147. China National Biotech Group Poliomyelitis Vaccine SWOT Analysis
Table 148. China National Biotech Group Recent Developments
Table 149. Eli Lilly Company Information
Table 150. Eli Lilly Description and Overview
Table 151. Eli Lilly Poliomyelitis Vaccine Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 152. Eli Lilly Poliomyelitis Vaccine Product and Services
Table 153. Eli Lilly Poliomyelitis Vaccine SWOT Analysis
Table 154. Eli Lilly Recent Developments
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Poliomyelitis Vaccine Distributors List
Table 158. Poliomyelitis Vaccine Customers List
Table 159. Poliomyelitis Vaccine Market Trends
Table 160. Poliomyelitis Vaccine Market Drivers
Table 161. Poliomyelitis Vaccine Market Challenges
Table 162. Poliomyelitis Vaccine Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Poliomyelitis Vaccine Product Picture
Figure 2. Global Poliomyelitis Vaccine Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Poliomyelitis Vaccine Market Share by Type in 2024 & 2034
Figure 4. Poliomyelitis Vaccine Ⅰ Product Picture
Figure 5. Poliomyelitis Vaccine Ⅱ Product Picture
Figure 6. Poliomyelitis Vaccine Ⅲ Product Picture
Figure 7. Oral Poliomyelitis Vaccine Product Picture
Figure 8. Global Poliomyelitis Vaccine Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 9. Global Poliomyelitis Vaccine Market Share by Application in 2024 & 2034
Figure 10. VAPP
Figure 11. VDPV
Figure 12. Poliomyelitis Vaccine Report Years Considered
Figure 13. Global Poliomyelitis Vaccine Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 14. Global Poliomyelitis Vaccine Revenue 2018-2034 (US$ Million)
Figure 15. Global Poliomyelitis Vaccine Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 16. Global Poliomyelitis Vaccine Sales Quantity 2018-2034 (K Units)
Figure 17. Global Poliomyelitis Vaccine Sales Quantity Market Share by Region (2018-2023)
Figure 18. Global Poliomyelitis Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 19. North America Poliomyelitis Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 20. North America Poliomyelitis Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 21. Europe Poliomyelitis Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. Europe Poliomyelitis Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 23. China Poliomyelitis Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. China Poliomyelitis Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 25. APAC Poliomyelitis Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. APAC Poliomyelitis Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 29. The Top 10 and Top 5 Players Market Share by Poliomyelitis Vaccine Sales Quantity in 2024
Figure 30. The Top 10 and Top 5 Players Market Share by Poliomyelitis Vaccine Revenue in 2024
Figure 31. Poliomyelitis Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 32. Global Poliomyelitis Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 33. Global Poliomyelitis Vaccine Revenue Market Share by Type (2018-2034)
Figure 34. Global Poliomyelitis Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 35. Global Poliomyelitis Vaccine Revenue Market Share by Application (2018-2034)
Figure 36. North America Poliomyelitis Vaccine Revenue Market Share by Company in 2024
Figure 37. North America Poliomyelitis Vaccine Sales Quantity Market Share by Company in 2024
Figure 38. North America Poliomyelitis Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 39. North America Poliomyelitis Vaccine Revenue Market Share by Type (2018-2034)
Figure 40. North America Poliomyelitis Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 41. North America Poliomyelitis Vaccine Revenue Market Share by Application (2018-2034)
Figure 42. North America Poliomyelitis Vaccine Revenue Share by Country (2018-2034)
Figure 43. North America Poliomyelitis Vaccine Sales Quantity Share by Country (2018-2034)
Figure 44. U.S. Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 45. Canada Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 46. Europe Poliomyelitis Vaccine Sales Quantity Market Share by Company in 2024
Figure 47. Europe Poliomyelitis Vaccine Revenue Market Share by Company in 2024
Figure 48. Europe Poliomyelitis Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 49. Europe Poliomyelitis Vaccine Revenue Market Share by Type (2018-2034)
Figure 50. Europe Poliomyelitis Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 51. Europe Poliomyelitis Vaccine Revenue Market Share by Application (2018-2034)
Figure 52. Europe Poliomyelitis Vaccine Revenue Share by Country (2018-2034)
Figure 53. Europe Poliomyelitis Vaccine Sales Quantity Share by Country (2018-2034)
Figure 54. Germany Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. France Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. U.K. Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. Italy Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 58. Russia Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 59. China Poliomyelitis Vaccine Sales Quantity Market Share by Company in 2024
Figure 60. China Poliomyelitis Vaccine Revenue Market Share by Company in 2024
Figure 61. China Poliomyelitis Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 62. China Poliomyelitis Vaccine Revenue Market Share by Type (2018-2034)
Figure 63. China Poliomyelitis Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 64. China Poliomyelitis Vaccine Revenue Market Share by Application (2018-2034)
Figure 65. APAC Poliomyelitis Vaccine Sales Quantity Market Share by Company in 2024
Figure 66. APAC Poliomyelitis Vaccine Revenue Market Share by Company in 2024
Figure 67. APAC Poliomyelitis Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 68. APAC Poliomyelitis Vaccine Revenue Market Share by Type (2018-2034)
Figure 69. APAC Poliomyelitis Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 70. APAC Poliomyelitis Vaccine Revenue Market Share by Application (2018-2034)
Figure 71. APAC Poliomyelitis Vaccine Revenue Share by Region (2018-2034)
Figure 72. APAC Poliomyelitis Vaccine Sales Quantity Share by Region (2018-2034)
Figure 73. Japan Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 74. South Korea Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. China Taiwan Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. India Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 78. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity Market Share by Company in 2024
Figure 79. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue Market Share by Company in 2024
Figure 80. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Poliomyelitis Vaccine Sales Quantity Share by Country (2018-2034)
Figure 85. Middle East, Africa and Latin America Poliomyelitis Vaccine Revenue Share by Country (2018-2034)
Figure 86. Brazil Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 87. Mexico Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 88. Turkey Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 89. Israel Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 90. GCC Countries Poliomyelitis Vaccine Revenue (2018-2034) & (US$ Million)
Figure 91. Poliomyelitis Vaccine Value Chain
Figure 92. Poliomyelitis Vaccine Production Process
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Distributors Profiles
Figure 95. Bottom-up and Top-down Approaches for This Report
Figure 96. Data Triangulation
Figure 97. Key Executives Interviewed